Compare · GKOS vs SYK
GKOS vs SYK
Side-by-side comparison of Glaukos Corporation (GKOS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $117.17B, about 16.1x GKOS ($7.30B).
- Over the past year, GKOS is up 25.3% and SYK is down 19.8% - GKOS leads by 45.1 points.
- GKOS has been more active in the news (11 items in the past 4 weeks vs 8 for SYK).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- Stryker Corporation
- Price
- $124.22+1.26%
- $305.46-1.06%
- Market cap
- $7.30B
- $117.17B
- 1M return
- -8.91%
- +3.71%
- 1Y return
- +25.26%
- -19.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest GKOS
- Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wen Leana was granted 1,878 shares, increasing direct ownership by 10% to 21,617 units (SEC Form 4)
- Director Weisner Aimee S was granted 1,878 shares, increasing direct ownership by 10% to 20,684 units (SEC Form 4)
- Director Torres Denice was granted 1,878 shares, increasing direct ownership by 8% to 24,212 units (SEC Form 4)
- Director Foley Mark J was granted 1,878 shares, increasing direct ownership by 3% to 60,267 units (SEC Form 4)
- Director Hoffmeister David F was granted 1,878 shares, increasing direct ownership by 4% to 49,549 units (SEC Form 4)
- Director Kliman Gilbert H was granted 1,878 shares, increasing direct ownership by 5% to 37,406 units (SEC Form 4)
- Director Stapley Marc was granted 1,878 shares, increasing direct ownership by 5% to 39,327 units (SEC Form 4)
- SEC Form SD filed by Glaukos Corporation
- Director Hoffmeister David F exercised 15,000 shares at a strike of $24.69, increasing direct ownership by 46% to 47,671 units (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation